Genentech: Dan Sutherlin | Vice President, Small Molecule Discovery Chemistry

A link to this page has been copied to your clipboard.

https://www.gene.com/scientists/our-scientists/dan-sutherlin

Paste this link in an email to share.

Ok

Scientists / Our Scientists

Years at Genentech

Publications

I started at Genentech in 1999 in what was then the Bioorganic Chemistry Department. I was attracted to Genentech based primarily on the people that were here, their enthusiasm for science, and the opportunity to work closely with world-class biologists. Since that time I have enjoyed the experience of working in many therapeutic areas (cardiovascular, oncology, immunology, and neuroscience) and on many different target classes including kinases, proteases, integrins, and ion-channels. In each project there have always been new and interesting challenges to overcome that has kept me curious about and engaged in the science of drug discovery.

Featured Publication

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer.

J. Med. Chem. 2011, 54:7579.

Daniel P Sutherlin, Linda Bao, Megan Berry, Georgette Castanedo, Irina Chuckowree, Jenna Dotson, Adrian Folks, Lori Friedman, Richard Goldsmith, Janet Gunzner, Timothy Heffron, John Lesnick, Cristina Lewis, Simon Mathieu, Jeremy Murray, Jim Nonomiya, Jodie Pang, Niel Pegg, Wei Wei Prior, Lionel Rouge, Laurent Salphati, Deepak Sampath, Qingping Tian, Vickie Tsui, Nan Chi Wan, Shumei Wang, Binqing Wei, Christian Wiesmann, Ping Wu, Bing-Yan Zhu, Alan Olivero.

View Abstract on PubMed

I am currently the research and development project leader of a new and exciting Pain target. Mutations in this ion channel have profound effects on pain.

The chance to participate in such an exciting area of science while being focused on a serious unmet medical need has been motivating.

Structure- and Ligand-Based Discovery of Chromane Arylsulfonamide Na v 1.7 Inhibitors for the Treatment of Chronic Pain

Journal of Medicinal Chemistry, ISSN: 15204804 00222623

Steven J. McKerrall; Teresa Nguyen; Kwong Wah Lai; Philippe Bergeron; Lunbin Deng; Antonio DiPasquale; Jae Chang; Jun Chen; Tania Chernov-Rogan; David Hackos; Jonathan M. Maher; Dan Ortwine; Jodie Pang; Jian Payandeh; Will Proctor; Shannon Shields; Jennifer Vogt; Pengfei Ji; Wenfeng Liu; Elisa Ballini; Lilia Schumann; Glauco Tarozzo; Girish Bankar; Sultan Chowdhury; Abid Hasan; Johnson; Kuldip Khakh; Sophia Lin; Charles J. Cohen; Christoph Dehnhardt; Brian Safina; Dan Sutherlin

Attention: This page may not render properly. The browser you are using, Internet Explorer 10, is no longer supported.

A link to this page has been copied to your clipboard.

Dan Sutherlin

Vice President, Small Molecule Discovery Chemistry

Featured Publication

Discovery of a Potent, Selective, and Orally Available Class I Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Kinase Inhibitor (GDC-0980) for the Treatment of Cancer.